Results for placebogruppen translation from Danish to English

i placebogruppen blev
in the placebo treatment group

sutent og placebogruppen).
sutent and placebo arms).

1000 patientår i placebogruppen.
in the ruth study, venous thromboembolic events occurred at a frequency of approximately 2.0% or 3.88 cases per 1000 patient-years in the raloxifene group and 1.4% or 2.70 cases per 1000 patient-years in the placebo group.

[87 til 97%]) for placebogruppen.
[87 to 97%]) for the placebo group.

6,0 (2,4) mmhg i placebogruppen.
1 mg/kg group, and -6.0 (2.4) in the placebo group.

14,5 % i placebogruppen, p=0,0041).
14.5% on the placebo arm, p=0.0041).

rsv indlæggelsesgraden var 10, 6% i placebogruppen.
the rsv hospitalisation rate was 10.6% in the placebo group.

ud af 1000 kvinder i placebogruppen ville ca.
1000

- behandlingsstandarden for placebogruppen i de pågældende undersøgelser
- the standard of care for the placebo group in the relevant studies;

der var ingen tilfælde af krampeanfald i placebogruppen.
there were no cases of seizures in the placebo group.

4, 6 og 4, 3 i infliximab - og placebogruppen.
mean baseline napsi scores were 4.6 and 4.3 in infliximab and placebo group.

i placebogruppen i uge 12, n = 36 e p = 0,028
for the placebo group at week 12, n = 36 e p = 0.028

2, 7 nye fingersår i placebogruppen (p= 0, 0042).
2.7 new digital ulcers in the placebo group (p = 0.0042).

2,2 gange længere end i placebogruppen (53 dage).
2.2-fold longer than in the placebo group (53 days).

6 af tilfældene optrådte i gardasilgruppen og 2 af tilfældene i placebogruppen.
among 11,813 subjects who received gardasil and 9,701 subjects who received placebo, there were 8 cases of non-specific arthritis reported, 6 in the gardasil group and 2 in the placebo group.

hos én patient i placebogruppen var synet i spontan bedring ved baseline.
one patient in the placebo group presented with ongoing spontaneous recovery of vision at baseline.

31, 2% og 21, 5% i live i tarceva - og placebogruppen.
the percent of patients alive at 12 months was 31.2% and 21.5%, for the tarceva and placebo groups, respectively.

ensure consistent writing of placebogruppen; please check throughout the document.
who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery ed

3, 4% i orlistatgruppen i forhold til 5, 4% i placebogruppen).
3.4% in the orlistat group compared to 5.4% in the placebo-treated group).

0, 5 forværringer årligt i xolair- gruppen og ca. én årligt i placebogruppen.
the first three studies showed that patients receiving xolair had around half as many exacerbations of asthma over the first 28 or 52 weeks of treatment, with around 0.5 exacerbations per year in the xolair group and around one per year in the placebo group.